In recent years, marijuana has transitioned from a stigmatized substance to a widely accepted form of recreation and medicine. As of February 2025, numerous states have legalized its use, both medically and recreationally. However, this shift has brought forth concerns regarding self-medication, over-prescription, increased potency, detection challenges, and the short- and long-term effects on users.
Self-Medication with Marijuana
Self-medication is when individuals use substances without medical guidance to alleviate symptoms of physical or mental health conditions. This trend is notably prevalent with marijuana due to its perceived safety and therapeutic potential. People commonly use marijuana to manage anxiety, depression, chronic pain, insomnia, and even symptoms of PTSD. This behavior is often fueled by anecdotal success stories and the growing cultural acceptance of cannabis use.
However, self-medicating with marijuana presents several risks. Individuals may unknowingly consume dosages that are too high, leading to increased tolerance, dependence, and even addiction. The absence of professional guidance also means that underlying medical conditions might go undiagnosed or improperly treated. For instance, using marijuana to manage anxiety could mask symptoms of a more serious mental health condition, such as bipolar disorder or major depressive disorder.
A 2024 study published in the Journal of Cannabis Research found that individuals with prior or current cannabis use were at least four times more likely to self-medicate. The study highlighted a concerning trend where individuals bypass traditional healthcare pathways, opting for self-directed marijuana use. This raises questions about the role of healthcare providers in educating patients about the risks and benefits of cannabis.
Moreover, long-term self-medication can lead to psychological dependence, where individuals feel incapable of managing their symptoms without marijuana. This reliance can contribute to decreased motivation, impaired cognitive function, and exacerbation of mental health issues. The lack of standardized dosing and the varying potency of cannabis products further complicate safe usage as there are no safeguards behind how often an individual re-ups on marijuana and no restrictions on the amount of marijuana/THC they are consuming. In addition the highly marketed products within these medicinal shops often use flashing colors and clever taglines to help sell the consumer on their product much like a generic candy or food would do to grab the attention of a potential buyer. This assists in allowing the product to masquerade itself as a recreational product instead of the medicine that it claims to be. The reality of this becomes especially unsettling for younger patients as these marketing tactics have been scrutinized by the tobacco industry, however the marijuana industry has yet to be held to the same standard.
To address these challenges, healthcare providers and public health officials must develop educational initiatives that inform consumers about the potential risks of self-medicating with marijuana. Emphasizing the importance of medical supervision and evidence-based treatment options could help mitigate the risks associated with unsupervised cannabis use.
While some users report relief, self-medication carries risks. Without medical supervision, individuals may consume inappropriate dosages or use marijuana to mask symptoms of underlying conditions, potentially delaying proper diagnosis and treatment. Moreover, reliance on marijuana for symptom management can lead to dependence and exacerbate mental health issues.
Over-Prescription of Medical Marijuana
The growing acceptance of marijuana as a therapeutic agent has led to an increase in medical prescriptions. In many regions, patients can obtain medical cannabis cards for a broad range of conditions, including chronic pain, anxiety, and insomnia. While marijuana can offer relief for certain conditions, there are growing concerns about over-prescription and inadequate medical oversight.
One contributing factor to over-prescription is the lack of standardized guidelines for dosing and usage. Unlike conventional pharmaceuticals, cannabis lacks robust clinical trials that inform safe prescribing practices. Consequently, some healthcare providers may prescribe marijuana without fully considering alternative treatments or evaluating potential risks, especially in vulnerable populations such as adolescents or individuals with a history of substance use disorders.
A 2024 article in StatPearls emphasized the need for comprehensive patient evaluations before prescribing marijuana. The article noted that cannabis use can cause intoxication, withdrawal, and various biopsychosocial issues, including psychosis and sleep disorders. It also highlighted that healthcare providers should be vigilant in monitoring patients for signs of dependency and adverse reactions. (ncbi.nlm.nih.gov)
Furthermore, the commercialization of cannabis has led to aggressive marketing practices that may influence prescribing behaviors. Dispensaries often promote high-potency products, edibles, and concentrates, which can lead to unintentional overconsumption and increased risk of dependency. This commercial influence can blur the line between medical necessity and recreational use, contributing to over-prescription.
To mitigate these risks, medical professionals need standardized guidelines for prescribing marijuana, including dosage recommendations and monitoring protocols. Continuing education programs should also be implemented to keep healthcare providers informed about the latest research on cannabis efficacy, safety, and potential interactions with other medications.
Moreover, policymakers should consider stricter regulations on medical cannabis advertising to prevent misleading claims about the benefits of marijuana. Ensuring that patients receive balanced and accurate information can help curb the trend of over-prescription while maintaining access for those who genuinely benefit from medical cannabis.
The medical community has increasingly recognized marijuana’s therapeutic potential. However, this recognition has led to concerns about over-prescription. Some healthcare providers may recommend marijuana without thoroughly evaluating alternative treatments or considering potential risks, especially in patients with a history of substance use disorders.
Increased Potency of Marijuana
One of the most significant changes in the cannabis industry over the past few decades is the dramatic increase in THC potency. THC, or tetrahydrocannabinol, is the primary psychoactive compound in marijuana responsible for its mind-altering effects. In the 1990s, the average THC content in marijuana was around 5%. Today, it ranges between 20-30%, with some concentrated products, such as dabs and oils, containing over 90% THC.
This rise in potency is largely due to advancements in cannabis cultivation and extraction techniques, which have enabled producers to create highly concentrated products. While this allows for more efficient delivery of therapeutic effects, it also poses significant risks, particularly for inexperienced users or those with mental health vulnerabilities.
A 2023 article from Yale Medicine linked high-potency cannabis to an increased risk of psychotic symptoms, especially among adolescents and young adults. The article highlighted that heavy and early use of potent cannabis is associated with a heightened risk of developing schizophrenia, bipolar disorder, depression, and anxiety. Additionally, high-THC products are more likely to cause severe short-term side effects such as paranoia, hallucinations, and panic attacks.
The increased potency of marijuana also raises concerns about addiction and dependency. Higher THC levels can lead to increased tolerance, requiring users to consume more to achieve the desired effects. This cycle can quickly escalate into dependence, where individuals feel unable to function without marijuana. According to a 2024 report from the National Institute on Drug Abuse (NIDA), about 30% of cannabis users develop some form of cannabis use disorder, with the risk being higher among those who start using in adolescence or consume high-potency products.
Moreover, the long-term health implications of using high-potency marijuana are not yet fully understood. Emerging research suggests potential cognitive impairments, including memory deficits and reduced attention spans. A 2023 publication by the Substance Abuse and Mental Health Services Administration (SAMHSA) indicated that frequent use of high-potency marijuana could result in permanent IQ loss, particularly when initiated during adolescence.
Given these risks, public health officials and policymakers face the challenge of balancing legalization with regulation. Implementing THC potency caps, standardizing labeling practices, and restricting the sale of ultra-concentrated products are potential strategies to mitigate the adverse effects of high-potency cannabis. Additionally, public education campaigns are needed to raise awareness about the risks associated with potent marijuana products, particularly among young and vulnerable populations.
Short and Long-Term Effects of Increased Marijuana Potency
The escalation in marijuana potency has heightened both its short- and long-term effects, posing significant public health concerns. Short-term effects are typically more intense and unpredictable, especially among inexperienced users or those consuming high-potency products. These effects can include severe anxiety, paranoia, hallucinations, and even acute psychosis. In extreme cases, high doses of THC have been linked to cannabis-induced psychotic episodes, which may require medical intervention.
A 2023 study published in the American Journal of Psychiatry found that young adults who used high-potency marijuana were at a significantly increased risk of developing psychotic symptoms compared to those who used lower potency products. The study emphasized the need for greater public awareness of the potential mental health risks associated with potent cannabis products. (ajp.psychiatryonline.org)
Long-term use of high-potency marijuana has been linked to various cognitive impairments, including memory deficits, reduced attention span, and impaired learning abilities. These cognitive deficits are particularly concerning for adolescents and young adults, whose brains are still developing. According to a 2024 report from the National Institute on Drug Abuse (NIDA), chronic marijuana use can result in permanent IQ loss of up to 8 points when initiated during adolescence, highlighting the need for targeted prevention programs.
Additionally, long-term marijuana use can contribute to mental health disorders such as depression, anxiety, and an increased risk of developing schizophrenia, particularly among individuals with a genetic predisposition. A 2024 review in The Lancet Psychiatry concluded that heavy cannabis use, especially high-potency variants, doubles the risk of developing psychotic disorders. (thelancet.com)
Physical health effects are also a concern. Chronic use of high-potency cannabis has been associated with respiratory issues, including chronic bronchitis and lung damage. Although vaping is often marketed as a safer alternative, studies have shown that high-concentration THC vapes can lead to lung injury, known as EVALI (E-cigarette or Vaping Use-Associated Lung Injury). In 2023, the Centers for Disease Control and Prevention (CDC) reported a resurgence of EVALI cases linked to illicit THC vape products containing harmful additives. (cdc.gov)
Furthermore, increased THC potency raises the risk of developing Cannabis Use Disorder (CUD), characterized by dependency and withdrawal symptoms. A 2024 study published in Addiction found that users of high-potency cannabis were four times more likely to develop CUD compared to those using lower potency products. Symptoms of CUD include irritability, sleep disturbances, cravings, and decreased motivation, which can significantly impact an individual’s quality of life. (onlinelibrary.wiley.com)
The long-term societal implications of increased marijuana potency are also noteworthy. Higher rates of dependency and mental health issues could place a significant burden on public health systems. Additionally, impaired cognitive function among long-term users may affect educational attainment and occupational performance, leading to broader socioeconomic consequences.
To mitigate these risks, public health officials should consider implementing potency caps, improving labeling practices, and launching targeted educational campaigns. These initiatives could help consumers make informed decisions and reduce the negative health impacts associated with high-potency marijuana products.
Brain Activity and Marijuana Use
A recent study published in JAMA Network Open investigated the association between cannabis use and mortality among adults aged 65 years and older receiving long-term opioid therapy. This population is particularly vulnerable due to the complex interactions between cannabis, opioids, and age-related health conditions. The study aimed to determine whether cannabis use impacted mortality rates within this demographic, considering the increasing trend of older adults using marijuana for pain management and other age-related symptoms.
The study analyzed data from over 10,000 participants, assessing cannabis use through self-reports and drug screenings. Researchers found that individuals who tested positive for cannabis had a 30% higher risk of short-term mortality compared to non-users. The increased risk was particularly pronounced among those with cardiovascular conditions, suggesting potential adverse interactions between cannabis and heart medications.
One explanation for this increased mortality risk is the potential for cannabis to amplify the sedative effects of opioids, leading to respiratory depression and overdose. Additionally, cannabis may affect heart rate and blood pressure, which can be dangerous for older adults with preexisting cardiovascular issues. The study also noted a higher incidence of falls and accidents among cannabis users, likely due to impaired coordination and cognitive function.
The findings underscore the importance of cautious marijuana use among older adults, particularly those on long-term opioid therapy. Healthcare providers should thoroughly evaluate the risks and benefits before recommending cannabis to this population. The study also highlights the need for further research to understand the long-term health effects of cannabis use in older adults and the potential interactions with commonly prescribed medications.
These results have significant implications for public health policy and medical practice. As the legalization of marijuana continues to expand, it is crucial to develop guidelines that address the unique needs and vulnerabilities of older adults. This includes educating healthcare providers about potential risks, standardizing screening procedures for cannabis use, and ensuring that older adults receive accurate information about the benefits and dangers of medical marijuana.
Challenges in Detecting Marijuana Impairment
One of the most significant challenges posed by the increasing use of marijuana is accurately detecting impairment. Unlike alcohol, where blood alcohol concentration (BAC) provides a clear measure of intoxication, no equivalent standard exists for marijuana. THC, the psychoactive compound in cannabis, is fat-soluble and can remain in the body long after the intoxicating effects have worn off. This makes it difficult to determine when someone is actively under the influence.
Current detection methods include blood, urine, saliva, and hair tests, which can identify the presence of THC or its metabolites. However, these tests cannot reliably indicate the level of impairment. For instance, frequent users may test positive long after they are no longer impaired, while occasional users may show lower levels despite being under the influence. This discrepancy presents significant challenges, particularly in safety-sensitive professions and activities like driving.
The inability to accurately measure marijuana impairment has legal and safety implications. In many states, law enforcement agencies rely on field sobriety tests and drug recognition experts to assess impairment. However, these methods are subjective and can lead to inconsistent outcomes. As a result, there is an urgent need for more accurate and reliable testing methods.
Recent advancements are being made in developing new technologies to detect marijuana impairment. In 2023, researchers at the University of California introduced a breathalyzer designed to measure THC levels in breath vapor. Preliminary studies showed promising results, but more extensive testing is required to validate its accuracy and reliability.
Another approach involves cognitive impairment assessments, such as digital apps that measure reaction times, memory recall, and motor coordination. These tools aim to provide a more comprehensive evaluation of impairment, but standardization and regulatory approval are needed before they can be widely adopted.
The challenges in detecting marijuana impairment also extend to workplace safety. Employers struggle to balance safety protocols with employee rights, particularly in states where marijuana is legal. Developing impairment standards and testing methods that are both accurate and non-invasive remains a priority for public safety officials and employers alike.
To address these issues, continued research and investment in new technologies are essential. Policymakers must also work towards establishing standardized impairment thresholds and updating regulations to reflect the evolving landscape of marijuana use. Until more accurate testing methods are developed, public education campaigns are crucial to emphasize the risks of driving or operating machinery while under the influence of marijuana.
Sources
- American Academy of Child and Adolescent Psychiatry. (n.d.). Marijuana and Teens. Retrieved from https://www.aacap.org/AACAP/Families_and_Youth/Facts_for_Families/FFF-Guide/Marijuana-and-Teens-106.aspx
- Di Forti, M., Quattrone, D., Freeman, T. P., Tripoli, G., Gayer-Anderson, C., Quigley, H., … & Murray, R. M. (2023). High-potency cannabis and the risk of psychosis. JAMA Network Open. Retrieved from https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2799636
- Galiatsatos, P. (2024). Not Your Grandmother’s Marijuana: Rising THC Concentrations in Cannabis Can Pose Devastating Health Risks. Yale Medicine. Retrieved from https://medicine.yale.edu/news-article/not-your-grandmothers-marijuana-rising-thc-concentrations-in-cannabis-can-pose-devastating-health-risks/
- JAMA Network Open. (2023). Association of a Positive Drug Screening for Cannabis With Mortality Among Adults Aged 65 Years and Older Receiving Long-term Opioid Therapy. Retrieved from https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2799636
- JAMA Network Open. (2024). Cannabis Use Disorder Emergency Department Visits and Mortality. Retrieved from https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2829914
- JAMA Network Open. (2024). Time to Act on Growing Public Health Threat of Cannabis Use Disorder. Retrieved from https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2829919
- National Center for Biotechnology Information. (2023). Cannabis Use Disorder – StatPearls. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK538131/
- Pharmacy Times. (2024). Study Finds Nearly 3 in 10 Individuals With Chronic Pain Use Cannabis. Retrieved from https://www.pharmacytimes.com/view/study-finds-nearly-3-in-10-individuals-with-chronic-pain-use-cannabis
- Satel, S. (2025). Legal Weed Didn’t Deliver on Its Promises. The Atlantic. Retrieved from https://www.theatlantic.com/ideas/archive/2025/01/marijuana-legalization-drawbacks/681519/
- Satel, S. (2024). Marijuana Is Too Strong Now. The Atlantic. Retrieved from https://www.theatlantic.com/ideas/archive/2024/08/high-potency-marijuana-regulation/679639/
